Astellas Pharma completes phase III in Japan for UMN-0502, a seasonal influenza vaccine

The recombinant seasonal influenza HA vaccine ASP7374 contains three different strains of antigens and has been produced by a cell-culture manufacturing method employing the Baculovirus Expression Vector System (BEVS). The vaccine was developed in collaboration with UMN Pharma.

Astellas Pharma news release, May 30, 2014

Astellas Pharma completes phase III in Japan for UMN-0502, a seasonal influenza vaccine
Scroll to top